Last checked at 20 Dec 2018 07:01
Renalytix AI PLC("RenalytixAI" or the "Company")
Planned appointment of joint broker and change of nominated adviser
Renalytix AI plc (AIM: RENX), a developer of artificial intelligence ("AI") enabled clinical diagnostics solutions for kidney disease, notes the announcement today by EKF Diagnostics Holdings plc (AIM: EKF) and confirms that it has agreed a different resolution to the requirement for one of the two companies to appoint a new nominated adviser.
The proposed change remains driven by the regulatory requirement for an AIM issuer to retain an independent nominated adviser. Following EKF Diagnostics Holdings plc's ("EKF") decision to invest in the placing which took place alongside the admission to trading on AIM of Renalytix AI plc ("RenalytixAI"), it was no longer possible for N+1 Singer to continue to act as an independent nominated adviser to both companies.
By mutual agreement of all parties, N+1 Singer will now remain nominated adviser and broker to EKF. To preserve the independence of its nominated adviser, RenalytixAI will appoint a new nominated adviser and joint broker, with US distribution capability which aligns with the Company's US-based business operations and the initial target market for its products.
N+1 Singer will continue to act as nominated adviser and broker to RenalytixAI in the interim, and as joint broker following the appointment of a joint broker and new nominated adviser. A further announcement will be made in the New Year with regard to the new appointment.
Enquiries:
Renalytix AI plc | www.renalytixai.com | ||
James McCullough, CEO | Via Walbrook PR or Tel: +1 646 397 3970 | ||
|
| ||
N+1 Singer (Nominated Adviser & Broker) | Tel: 020 7496 3000 | ||
Aubrey Powell / James White / George Tzimas (Corporate Finance)Tom Salvesen (Corporate Broking)
|
| ||
Walbrook PR Limited | Tel: 020 7933 8780 or renalytix@walbrookpr.com | ||
Paul McManus / Lianne Cawthorne | Mob: 07980 541 893 / 07584 391 303 | ||
|
|
| |
About RenalytixAI
RenalytixAI is a developer of artificial intelligence-enabled clinical diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company's solutions are being designed to make significant improvements in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. For more information, visit renalytixai.com.